Skip to main content

Posts

Stop Guessing What a Stock Is Worth

FAST Graphs helps investors visualize a company’s earnings, valuation, dividends, and historical performance in one clear research platform. Compare price with fundamentals, identify potential overvaluation or undervaluation, and make decisions with greater confidence.

Research the business behind the stock.

Explore FAST Graphs Today

Disclosure: This advertisement may contain an affiliate link. I may earn a commission at no additional cost to you.

Featured post

Accenture’s Talent Model Faces Its Biggest Technological Disruption in Decades

For most of its modern history, Accenture has operated one of the most recognizable talent machines in corporate life. It recruits at enormous scale, brings in armies of ambitious graduates, teaches them a common language of frameworks and delivery methods, places them on client work, and gradually moves the strongest performers upward. Some become specialists. Some become managers. A smaller number become managing directors. A still smaller number learn how to say “enterprise-wide transformation” without visibly needing oxygen. The model has survived mainframes, personal computers, the internet, outsourcing, cloud computing, mobile technology, automation, and every corporate trend that briefly required a new practice area and an updated PowerPoint template. Each technological wave changed what Accenture sold, but the basic human architecture remained remarkably durable: large numbers of junior people performed the labor-intensive work at the bottom, experienced managers coordinated it...
Recent posts

Accenture’s AI Opportunity Isn’t About Chatbots—It’s About Rebuilding Corporate America

Why I believe the real prize for Accenture is not selling companies another clever interface, but helping them reconstruct the machinery beneath the modern enterprise. When most people hear “artificial intelligence,” they still picture a chatbot. They imagine an employee typing a question into a box, getting a polished answer in seconds, and saving a little time on an email or presentation. That is the most visible expression of AI, so naturally it receives most of the attention. It is also, in my view, the least interesting part of the opportunity now sitting in front of Accenture. The chatbot is the showroom. The real business is behind the walls. Corporate America is full of old software, fragmented databases, manual approvals, conflicting policies, duplicated work, and systems that were never designed to communicate with one another. Many large companies have spent decades adding technology without removing much of what came before it. They operate with modern websites sitting on t...

ACADIA’s Rare-Disease Ambitions Could Reshape the Company’s Growth Profile

When I first look at ACADIA Pharmaceuticals, I see a company that has already accomplished something many biotechnology businesses never manage to do: It has moved beyond the PowerPoint stage. ACADIA has actual products, actual revenue, and actual patients using its medicines. That may sound like a low bar until I remember how many biotechnology companies spend years discussing enormous addressable markets while producing little besides clinical-trial expenses and increasingly imaginative investor presentations. ACADIA is different. NUPLAZID has established the company in Parkinson’s disease psychosis, while DAYBUE has given it a commercial position in Rett syndrome. Those two products generated combined second-quarter 2026 revenue of approximately $308 million. Management raised its full-year revenue guidance to between $1.24 billion and $1.30 billion, including projected DAYBUE sales of $480 million to $510 million and NUPLAZID sales of $760 million to $790 million. ACADIA’s second-q...

ACADIA’s Pipeline Math: What Future Indications Could Be Worth to Shareholders

When I look at ACADIA Pharmaceuticals, I see a company that has already crossed one of biotechnology’s most dangerous borders: it has stopped being a clinical-stage promise factory and become a commercial business. That distinction matters. ACADIA has two approved products, growing revenue, positive net income, and enough cash to fund a serious development program without immediately passing a collection plate among shareholders. It also has a pipeline capable of changing the company’s long-term value—assuming, as always, that biology agrees to cooperate. That last condition deserves emphasis. Biotechnology investors have a charming habit of treating every clinical program as an approved blockbuster temporarily inconvenienced by the absence of evidence. A compound enters Phase 2, management displays an enormous patient population, and somebody multiplies that population by the annual treatment cost. By lunchtime, the drug is supposedly worth $12 billion. Actual drug development is less...